CN116847839A - 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌 - Google Patents

使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌 Download PDF

Info

Publication number
CN116847839A
CN116847839A CN202280012941.XA CN202280012941A CN116847839A CN 116847839 A CN116847839 A CN 116847839A CN 202280012941 A CN202280012941 A CN 202280012941A CN 116847839 A CN116847839 A CN 116847839A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
combination therapy
gdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280012941.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·梅特卡夫
林葵
M·A·哈夫纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN116847839A publication Critical patent/CN116847839A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280012941.XA 2021-02-16 2022-02-14 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌 Pending CN116847839A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149947P 2021-02-16 2021-02-16
US63/149,947 2021-02-16
PCT/US2022/016254 WO2022177835A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Publications (1)

Publication Number Publication Date
CN116847839A true CN116847839A (zh) 2023-10-03

Family

ID=80682672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280012941.XA Pending CN116847839A (zh) 2021-02-16 2022-02-14 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌

Country Status (6)

Country Link
US (1) US20230381156A1 (https=)
EP (1) EP4294393A1 (https=)
JP (1) JP2024506347A (https=)
CN (1) CN116847839A (https=)
TW (1) TWI881203B (https=)
WO (1) WO2022177835A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN113194941A (zh) * 2018-12-19 2021-07-30 基因泰克公司 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌

Also Published As

Publication number Publication date
EP4294393A1 (en) 2023-12-27
TWI881203B (zh) 2025-04-21
WO2022177835A1 (en) 2022-08-25
TW202237099A (zh) 2022-10-01
JP2024506347A (ja) 2024-02-13
US20230381156A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
US20230330106A1 (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
US20230381155A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
AU2021272100B2 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
US20230381156A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib
TWI828060B (zh) 使用包含gdc-9545及阿貝西尼或瑞博西尼之組合療法治療乳癌
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
HK40098151A (zh) 使用包括gdc-9545以及阿贝西利或者瑞博西尼的组合疗法治疗乳腺癌
HK40101173A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101825

Country of ref document: HK